Royalty Pharma Plc (RPRX)

NASDAQ


	Symbol		Exchange		Currency
	RPRX		NASDAQ		USD	Real-time
	RPDG		TradeGate		EUR	Delayed

Currency in USD

Disclaimer

27.75

0.00(0.00%)

Closed05/10

After Hours

27.97+0.22(+0.79%)

05/10

Fair Value

Day's Range

27.62

27.93

52 wk Range

25.20

31.66

RPRX Income Statement

Featured here, the Income Statement (earnings report) for Royalty Pharma Plc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

2,237.22

2,354.55

Total Revenues Growth

-2.28%

+5.24%

Cost Of Revenues

904.24

560.66

Gross Profit

1,332.97

1,793.9

Gross Profit Growth

-27.42%

+34.58%

Gross Profit Margin %

59.58%

76.19%

Other Operating Expenses, Total

410.08

301.75

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+1.03%	-26.42%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	177.11	52
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	227.3	249.75
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-

Operating Income

922.89

1,492.15

Operating Income Growth

-35.49%

+61.68%

EBIT Margin %

41.25%

63.37%

Net Interest Expenses

-109.63

-114.9

Net Interest Expenses Growth

+2.65%

-4.81%

Interest Expense, Total

-187.96

-187.19

Interest And Investment Income

78.34

72.29

Other Non Operating Expenses, Total

72.88

4.86

EBT, Excl. Unusual Items

886.15

1,382.11

Gain (Loss) On Sale Of Assets

-

-

Other Unusual Items, Total

-615.83

-

EBT, Incl. Unusual Items

230.06

1,700.09

EBT, Incl. Unusual Items Growth

-81.46%

+638.96%

EBT, Incl. Unusual Items Margin

10.28%

72.2%

Income Tax Expense

-

-

Net Income to Company

230.06

1,700.09

Minority Interest

-187.23

-565.25

Net Income

42.83

1,134.83

Net Income Growth

-93.09%

+2,549.5%

Net Income Margin %

1.91%

48.2%

Preferred Dividend and Other Adjustments

-

-

Net Income to Common Excl. Extra Items

42.83

1,134.83

Basic EPS - Continuing Operations

0.1

2.54

Basic EPS - Continuing Operations Growth

-93.45%

+2,492.45%

Diluted EPS - Continuing Operations

0.1

2.53

Diluted EPS - Continuing Operations Growth

-93.44%

+2,490.73%

Basic Weighted Average Shares Outstanding

437.96

447.6

Diluted Weighted Average Shares Outstanding

437.97

602.9

Dividend Per Share

0.76

0.8

Dividend Per Share Growth

+11.76%

+5.26%

EBITDA

928.56

1,497.82

EBITDA Growth

-36.12%

+61.31%

EBITDA Margin %

41.51%

63.61%

EBIT

922.89

1,492.15

* In Millions of USD (except for per share items)

24,795.75

-218.85

-0.87%

81,050.00

-638.45

-0.78%

50,478.90

-983.15

-1.91%

Nifty 50 Futures

25,140.00

-187.20

-0.74%

5,723.20

-27.9

-0.48%

8,316.68

+36.05

+0.44%

102.344

+0.069

+0.07%